Related Experiment Videos
Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy
Christy M Isler1, P Scott Barrilleaux, Brian K Rinehart
1Department of Obstetrics and Gynecology, East Carolina University Brody School of Medicine, Greenville, North Carolina 27858-4354, USA. islerc@mail.ecu.edu
Obstetrics and Gynecology
|January 9, 2003
Summary
Clinical symptoms can safely shorten postpartum magnesium sulfate use for seizure prevention in hypertensive disorders of pregnancy. This approach avoids arbitrary protocols, ensuring patient safety and efficient treatment.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Maternal-Fetal Medicine
Background:
- Pregnancy-related hypertensive disorders, including preeclampsia and eclampsia, necessitate seizure prophylaxis.
- Magnesium sulfate is a standard treatment, but its optimal duration postpartum is debated.
- Current protocols for magnesium sulfate cessation are often arbitrary.
Purpose of the Study:
- To establish clinical parameters for discontinuing postpartum magnesium sulfate seizure prophylaxis.
- To evaluate the efficacy and safety of a clinical criteria-based approach.
Main Methods:
- Prospective study involving 503 patients with hypertensive disorders of pregnancy.
- Utilized specific clinical symptoms (headache, visual changes, epigastric pain) and signs (blood pressure, diuresis) for magnesium sulfate cessation.
- Excluded laboratory assessments like proteinuria from discontinuation criteria.
Main Results:
- No significant difference in magnesium sulfate duration across hypertensive disorder subgroups (median 4 hours).
- No eclamptic seizures occurred post-discontinuation.
- 7.6% of patients required magnesium reinstitution due to blood pressure exacerbation with symptoms.
Conclusions:
- Clinical criteria provide a successful and safe method to shorten postpartum magnesium sulfate duration.
- This approach is superior to arbitrary protocols for managing seizure prophylaxis in hypertensive disorders of pregnancy.